Q-omics provides the consensus-scored DRD1 profile across patient tissues and cancer cell-line models. DRD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DRD1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DRD1 RNA expression shows 12,548 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LIHC, KIRC, and SARC as cancer lineages where DRD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DRD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DRD1 survival associations across molecular data types. DRD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DRD1 RNA expression–survival associations across cancer types. High DRD1 expression shows unfavorable associations in UVM and HNSC, but favorable associations in LIHC, ACC, BLCA and PRAD. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DRD1 RNA expression.
This table summarizes DRD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DRD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DRD1 shows lower tumor expression in KIRC, THCA, KIRP, KICH and LUSC and higher tumor expression in STAD. The KIRC box plot shows higher DRD1 RNA expression in normal versus tumor tissue (log2 FC = −0.626, t-test p < 0.001).
This table shows molecular features associated with DRD1 in patient tissues and cancer cell lines. In patient samples, DRD1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, DRD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
